- Home
- TRDA
as 11-15-2024 4:00pm EST
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 609.7M | IPO Year: | 2021 |
| Target Price: | $23.33 | AVG Volume (30 days): | 132.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.75 - $20.49 | Next Earning Date: | 11-05-2024 |
| Revenue: | $215,232,000 | Revenue Growth: | 146.92% |
| Revenue Growth (this year): | 47.63% | Revenue Growth (next year): | -74.36% |
Stock Insider Trading Activity of Entrada Therapeutics Inc. (TRDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Nov 11 '24 | Sell | $19.98 | 8,637 | $172,562.08 | 73,849 | |
| Sethuraman Natarajan | TRDA | President, Research & Develop. | Nov 11 '24 | Sell | $20.02 | 4,109 | $82,299.94 | 163,588 | |
| Sethuraman Natarajan | TRDA | President, Research & Develop. | Oct 16 '24 | Sell | $18.00 | 600 | $10,800.00 | 163,588 | |
| Dowden Nathan J | TRDA | President & COO | Sep 26 '24 | Sell | $16.00 | 847 | $13,552.00 | 125,149 | |
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Sep 9 '24 | Sell | $14.97 | 3,195 | $47,832.35 | 73,849 | |
| Dowden Nathan J | TRDA | President & COO | Sep 6 '24 | Sell | $15.13 | 2,303 | $34,752.92 | 125,149 | |
| Sethuraman Natarajan | TRDA | Chief Scientific Officer | Sep 6 '24 | Sell | $15.16 | 3,242 | $49,003.59 | 163,588 |
Latest Entrada Therapeutics Inc. News
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Entrada Therapeutics Insider Sold Shares Worth $339,281, According to a Recent SEC Filing
Simply Wall St.
11 days ago
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
12 days ago
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
12 days ago
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
GlobeNewswire
a month ago
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
GlobeNewswire
2 months ago
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
GlobeNewswire
2 months ago
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
Simply Wall St.
3 months ago
Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically
Compare TRDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.